Special population use of Pemigatinib
The use of Pemigatinib in special populations needs to be adjusted according to pregnancy, lactation, liver and kidney function, and other factors, involving contraceptive requirements, dosage modifications, and monitoring measures to ensure treatment safety and effectiveness.
1. Medication during pregnancy
(1) Based on its mechanism of action and animal data, pemetrexed may cause harm to fetuses and is contraindicated for pregnant women.
(2) Before treatment, it is necessary to confirm the pregnancy status of women of childbearing age, and effective contraceptive measures should be taken during the medication period and one week after discontinuation.
2. Medication during lactation
(1) It is not yet clear whether the medication has entered the breast milk. It is recommended to suspend breastfeeding during the treatment period and within one week after the last administration.
(2) It is necessary to weigh the benefits of breastfeeding against the potential risk of adverse reactions in infants.
3. Medication for people of childbearing age
(1) When the partner of a male patient is a woman of childbearing age, barrier contraception methods such as condoms should be used during medication and one week after discontinuation.
(2) Female patients should undergo pregnancy testing before taking medication to avoid using hormonal contraceptives (which may reduce their effectiveness).
4. Pediatric medication
(1) The safety and efficacy of using it for patients under 18 years old have not been established and is not recommended.
(2) There is a lack of research data on adjusting doses for children based on their body surface area or weight.
5. Elderly medication
(1) Patients aged 65 and above do not require routine dose adjustments, but close monitoring of adverse reactions is necessary.
(2) Elderly patients often take concomitant medications, and attention should be paid to the risk of drug interactions.
6. Medication for patients with liver dysfunction
(1) Mild damage (Child Pugh A grade) does not require dose adjustment.
(2) Moderate to severe damage (Child Pugh B/C grade) requires a 50% reduction and strengthened liver function monitoring.
7. Medication for patients with renal insufficiency
(1) Mild to moderate damage (eGFR ≥ 30mL/min) does not require dose adjustment.
(2) Severe damage or insufficient data on dialysis patients, it is recommended to use with caution and monitor for adverse reactions.
Disclaimer：《Special population use of Pemigatinib》Edited and sorted by Seagull Pharmacy's editors. Please contact us in time if there is any infringement. In addition, the suggestions for drug usage, dosage and disease mentioned in the article are only for medical staff's reference, and can not be used as any basis for medication！